AAIC 2023 – Acumen’s new amyloid approach impresses

[cafead]

via The amyloid-lowering era in Alzheimer’s might be only just beginning, but some groups are already trying to improve on existing antibodies. One such company is Acumen, which saw its stock rise 55% yesterday on promising phase 1 data presented at AAIC over the weekend.

article source